TMCnet News
PixarBio Corporation to Present at the 9th Annual LD Micro Main Event on December 6th in Bel Air, CAPixarBio Corporation, (OTCQX: PXRB) developers of NeuroReleaseTM, a novel morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018, announced today that CEO Frank Reynolds will be presenting at the 9th annual LD Micro Main Event in Bel Air, California on Tuesday, December 6, 2016
About LD Micro
The NeuroReleaseTM Platform: Non-Addictive
and Non-opiate Treatment of Pain Major Benefits of NeuroReleaseTM
Therefore, patients will maintain two-point discriminate touch, control of their locomotion nerve fibers so they control voluntary movement to enter rehabilitation quickly with a non-addictive morphine replacement. PixarBio's NeuroReleaseTM pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroReleaseTM is biodegradable, and it's non-toxic so NeuroReleaseTM can be re-injected to extend treatment timelines. PixarBio Corporation was awarded the Boston Business Journal's "2016 Best Places to Work". The award recognizes PixarBio as one of the region's best firms, offering the greatest professional opportunities and work environments to innovate.
About PixarBio Corporation
Safe Harbor Statement Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio's corporate headquarters at 200 Boston Ave, Suite 1875 in Medford, MA 02155. View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005007/en/ |